Molecular Templates

πŸ“ Austin, United StatesπŸ—“ Founded 2001πŸ‘₯ 196 employeesπŸ’° Last funded May 2018
Molecular Templates, Inc. (MTEM) is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform with unique mechanisms of actions which are highly differentiated from antibody drug conjugates (ADCs). MTEM is developing MT-6402, which is in a Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients; MT-5111, which is in a Phase I clinical trial for the treatment of HER2-positive cancers; and MT-0169, which is in a Phase I clinical trial to treat relapsed/refractory myeloma. MTEM’s pipeline of ETBs in development for other targets include CTLA-4, TIGIT, TROP2, and BCMA. MTEM has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas. It also has an office in New York, NY.
3
Total investors
0
Early stage
2
Mid stage
1
Late stage
2001
Founded
Investor geography1 country
United States
3
Investor activity2013–2018 Β· investors recorded per year
201312014120181
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Molecular Templates?
Molecular Templates has 3 investors on record on gritt.io, 2 mid-stage and 1 late-stage investors.
When did Molecular Templates last raise funding?
The most recent investment in Molecular Templates recorded on gritt.io was in May 2018.
When was Molecular Templates founded?
Molecular Templates was founded in 2001.
What industry is Molecular Templates in?
Molecular Templates operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Molecular Templates based?
Molecular Templates is headquartered in Austin, United States.